EverPoint Asset Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

EverPoint Asset Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-75,000	Closed	-$3.1M	–	535
2016 Q2	$3.1M	Buy	+75,000	New	+$3.26M	0.06%	284
2015 Q4	–	Sell	-100,000	Closed	-$1.54M	–	560
2015 Q3	$1.54M	Sell	100,000 -140,000	-58%	-$3.01M	0.04%	346
2015 Q2	$5.96M	Sell	240,000 -110,384	-32%	-$2.46M	0.11%	251
2015 Q1	$8.01M	Buy	350,384 +200,384	+134%	+$5.06M	0.15%	197
2014 Q4	$4.05M	Buy	+150,000	New	+$2.58M	0.09%	280

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EverPoint Asset Management's FPRX Position: Q3 2016 in Review

EverPoint Asset Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q3 2016, closing a stake of 75,000 shares — an estimated $3.1M sold.

EverPoint Asset Management first reported a position in FPRX in Q4 2014 and held it in 5 quarters. The position peaked at $8.01M in Q1 2015. 176 funds tracked by Wall St. Rank hold FPRX as of Q3 2016.

EverPoint Asset Management reported no remaining Five Prime Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
EverPoint Asset Management sold 75,000 Five Prime Therapeutics, Inc. shares in Q3 2016, an estimated $3.1M.
EverPoint Asset Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2014 and held it in 5 quarters.
EverPoint Asset Management's Five Prime Therapeutics, Inc. position peaked at $8.01M in Q1 2015.
176 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q3 2016.

Based on EverPoint Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.